A new oral medicine for enteric hyperoxaluria
Part of Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental oral medicine called TRA16 for people with enteric hyperoxaluria—a condition where the gut absorbs too much oxalate, leading to high levels in the urine and raising the risk of kidney stones. The goal is to see if the drug safely reduces urine oxalate levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had a recent 24-hour urine test showing your urine oxalate level is 50 mg or more.
- You must not have a genetic form of hyperoxaluria (primary hyperoxaluria) or known gene mutations like AGXT, GRHPR, or HOGA1.
- You must not have severe kidney problems (defined as eGFR below 30).
- You must be willing to sign a consent form and understand the study's procedures and possible side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how problems in the gut can lead to kidney stone risk, especially in people with inflammatory bowel disease or after certain weight-loss surgery. Your participation may help researchers understand the gut–kidney connection and identify why stones happen.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
Hear when a new Enteric Hyperoxaluria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.